百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02615 百利天恒

待上市 01-14 16:00:00

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本4.22亿
成交额0.00	换手率0.00%	流通股本4.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1768377600000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"01-14 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1768354200000,1768363200000],[1768366800000,1768377600000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":335,"timestamp":1768374000000,"preClose":343.89,"halted":0,"volume":1882900,"delay":0,"premium":"-100.00"}},"requestUrl":"/m/hq/s/02615","defaultTab":"news","newsList":[{"id":"2602933518","title":"JPM 2026前瞻 | 中国创新药站上全球舞台中央","url":"https://stock-news.laohu8.com/highlight/detail?id=2602933518","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602933518?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:58","pubTimestamp":1768208280,"startTime":"0","endTime":"0","summary":"2026年第44届摩根大通医疗健康大会将于1月12日至15日在美国旧金山举行。据披露，本届JPM的议题与参会企业或将高度集中于六大核心领域，其中生物技术板块占比最高，预计接近35%。目前，已有多家国内企业确认参会，且覆盖CXO与创新药两大核心群体。从行业趋势看，本届JPM或将进一步强化两条技术主线。进入2026年，这一趋势仍在延续。宜联生物B7H3 ADC授权给罗氏此次JPM 2026将成为国内药企集中展示核心分子竞争力、推动海外BD合作的重要窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06160","02269","LU2328871848.SGD","03696","BK1583","06978","09995","02359","BK1161","LU1969619763.USD","09688","01530","01276","02615"],"gpt_icon":0},{"id":"2602559242","title":"医药生物行业跟踪周报：“十五五”聚焦脑机接口，抢占全球科技高地，建议关注：微创脑科学、翔宇医疗、美好医疗等【东吴医药朱国广团队】","url":"https://stock-news.laohu8.com/highlight/detail?id=2602559242","media":"国广有话说","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602559242?lang=zh_cn&edition=full","pubTime":"2026-01-11 21:24","pubTimestamp":1768137841,"startTime":"0","endTime":"0","summary":"海内外共振，加速抢占全球科技高地：脑机接口技术当前已经成为全球各国科技竞争的战略高地之一。当前全球脑机接口真处于爆发前夜，我国脑机接口产业有望迎来黄金发展期，建议关注微创脑科学、翔宇医疗、美好医疗等。从自免角度，建议关注康诺亚、益方生物、一品红等。从创新药龙头角度，建议关注百济神州、恒瑞医药等。从医疗器械角度，建议关注联影医疗、鱼跃医疗等。从中药角度，建议关注佐力药业、方盛制药、东阿阿胶等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","02228","BK1161","BK1141","BK1515","02172","BK1574","09926","02615","BK1100","03933","BK1617","09995","09939"],"gpt_icon":0},{"id":"2602536916","title":"每周股票复盘：百利天恒（688506）EGFR×HER3双抗ADC纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536916","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536916?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:57","pubTimestamp":1768075027,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，百利天恒报收于343.9元，较上周的323.1元上涨6.44%。本周关注点公司公告汇总：iza-bren用于治疗食管鳞癌被纳入优先审评程序。公司公告汇总四川百利天恒药业股份有限公司自主研发的注射用iza-bren被国家药品监督管理局药品审评中心纳入优先审评品种名单，适用于既往经PD-1/PD-L1单抗联合含铂化疗治疗失败的复发性或转移性食管鳞癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","02615","BK0239"],"gpt_icon":0},{"id":"2602790343","title":"百利天恒拟不超2亿元回购股份，63岁董事长朱义暂无减持计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2602790343","media":"瑞财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602790343?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:31","pubTimestamp":1767947495,"startTime":"0","endTime":"0","summary":"瑞财经 严明会近日，百利天恒公告称，拟以集中竞价交易方式回购股份，金额不低于10000万元、不超过20000万元，价格不超过546元/股。回购期限自董事会审议通过方案起12个月内。目前，董监高、控股股东等未来3、6个月暂无减持计划。百利天恒董事长及总经理朱义，1963年12月出生，今年63岁，于1996年8月创立集团，曾于1987年至1990年在华西医科大学微生物学与免疫学教研室任教。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163142a7067628&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163142a7067628&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","02615"],"gpt_icon":0},{"id":"2601363384","title":"百利天恒：首次回购14858股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363384","media":"南方财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601363384?lang=zh_cn&edition=full","pubTime":"2026-01-08 18:48","pubTimestamp":1767869297,"startTime":"0","endTime":"0","summary":"南财智讯1月8日电，百利天恒公告，2026年1月8日公司通过集中竞价交易方式首次回购公司股份14,858股，占公司总股本的比例为0.0036%，回购成交的最高价为341.05元/股，最低价为332.81元/股，支付的资金总额为499.97万元（不含印花税、交易佣金等交易费用）。本次回购股份符合法律法规的规定及公司回购股份方案的要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601083612915036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","688506","BK0239","91194"],"gpt_icon":0},{"id":"2601351333","title":"交易总额突破1300亿美元！2025年全球创新药BD交易全景分析及趋势预判","url":"https://stock-news.laohu8.com/highlight/detail?id=2601351333","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601351333?lang=zh_cn&edition=full","pubTime":"2026-01-08 09:55","pubTimestamp":1767837325,"startTime":"0","endTime":"0","summary":"本文将基于药渡咨询的深度调研数据，对2025年全球及中国创新药BD交易的全景进行深度剖析，并对未来五年的发展趋势进行前瞻性预判。全景回顾：全球与中国BD交易的双向奔赴1.交易规模：中国领跑全球增长2025年，全球生物医药BD授权交易呈现出显著的回暖与扩张态势。此次交易总金额高达42.3亿美元，直接推动荣昌生物股价在两周内涨幅超105%。结 语2025年标志着中国创新药BD交易从“量变”走向“质变”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108095949a700da8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09926","09995","06978","02615","BK1574"],"gpt_icon":0},{"id":"2601872229","title":"百利天恒：关于取得金融机构股票回购专项贷款承诺函的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2601872229","media":"证券日报","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601872229?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:11","pubTimestamp":1767784284,"startTime":"0","endTime":"0","summary":"证券日报网讯1月7日，百利天恒发布公告称，近日，公司取得中国银行股份有限公司四川省分行出具的《贷款承诺函》，主要内容如下：1、贷款承诺额度：不超过1.8亿元人民币。2、贷款期限：3年。3、贷款用途：专项用于回购公司股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611616331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK0239","688506","02615","BK4211","FISI"],"gpt_icon":0},{"id":"2601186053","title":"百利天恒(688506.SH)：iza-bren(EGFR×HER3双抗ADC)用于治疗复发性或转移性食管鳞癌被纳入优先审评程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186053","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601186053?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:53","pubTimestamp":1767689624,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，近日，公司自主研发的全球首创(First-in-class)、新概念(New concept)且唯一进入III期临床阶段的EGFR×HER3双抗ADC(注射用iza-bren)被国家药品监督管理局药品审评中心(简称“CDE”)纳入优先审评品种名单。根据公开资料查询，iza-bren也是全球首个被纳入优先审评品种名单的EGFR×HER3双抗ADC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","688506","BK4231","91194","BK4080","02615","BK0239"],"gpt_icon":0},{"id":"2601855752","title":"百利天恒（688506）2.98亿股限售股将于1月6日解禁，占总股本72.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601855752","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601855752?lang=zh_cn&edition=full","pubTime":"2026-01-06 08:11","pubTimestamp":1767658269,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，百利天恒于1月6日将有2.98亿股限售股份解禁，为公司首发原股东限售股份，占公司总股本72.2%。最近一年内，该股累计解禁1244.01万股，占总股本的3.01%。本次解禁后，公司还有1187.38万股限售股份，占总股本2.88%。百利天恒主营业务：药品的研发、生产与营销。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600006230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","91194","688506","BK0239"],"gpt_icon":0},{"id":"2601020887","title":"【读财报】A股1月逾2800亿元解禁 百利天恒、海博思创解禁规模居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2601020887","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601020887?lang=zh_cn&edition=full","pubTime":"2026-01-05 07:12","pubTimestamp":1767568375,"startTime":"0","endTime":"0","summary":"新华财经北京1月5日电2026年1月，A股有117家公司的限售股面临解禁，合计解禁量约为102.02亿股，解禁规模2895.87亿元，环比下降约14.13%，同比上升约12.57%。其中，百利天恒解禁规模居首，解禁市值超900亿元。从行业分布来看，医药生物、电力设备、汽车行业解禁市值分别位列前三。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608072267.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","02615","159982","688411","399300","688506"],"gpt_icon":0},{"id":"2600028072","title":"下周超1600亿元解禁来袭，3股解禁市值超百亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2600028072","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600028072?lang=zh_cn&edition=full","pubTime":"2026-01-04 19:21","pubTimestamp":1767525660,"startTime":"0","endTime":"0","summary":"　　经Wind统计，1月5日—9日这周，A股共有37家公司限售股迎来解禁，合计解禁市值超1600亿元。　　从单只个股解禁规模来看，有16股解禁市值超10亿元。　　其中，百利天恒解禁市值居首，限售股将在1月6日解禁，解禁市值约为963.19亿元，解禁股份类型为首发原股东限售股份，解禁股东为公司控股股东、实际控制人朱义，解禁数量占总股本比例为72.2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-04/doc-inhfcxwm2786911.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-04/doc-inhfcxwm2786911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02615"],"gpt_icon":0},{"id":"2600015362","title":"专访百利天恒创始人朱义：原始创新打造超级爆品，执掌全球话语权","url":"https://stock-news.laohu8.com/highlight/detail?id=2600015362","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600015362?lang=zh_cn&edition=full","pubTime":"2026-01-03 19:40","pubTimestamp":1767440400,"startTime":"0","endTime":"0","summary":"行业热度攀升，百利天恒创始人朱义向21世纪经济报道记者分析，“对于本土Biotech而言，关键机会在于聚焦从0到1的原始创新，在未被满足的临床需求领域建立核心技术壁垒，实现从跟跑到领跑的跨越。”朱义表示，这背后是百利天恒针对iza-bren在国内开展的临床研究，始终严格遵循国际标准推进的扎实积累。朱义透露，后续将在合适时机重启港股IPO上市，计划通过全球资本平台支撑企业长期全球化发展战略。其二，全球临床开发能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103194608a6ee74db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103194608a6ee74db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","91194"],"gpt_icon":0},{"id":"2600019115","title":"得润电子将被实施其他风险警示！超1600亿元解禁洪流来袭 3股压力大","url":"https://stock-news.laohu8.com/highlight/detail?id=2600019115","media":"数据宝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600019115?lang=zh_cn&edition=full","pubTime":"2026-01-03 07:46","pubTimestamp":1767397570,"startTime":"0","endTime":"0","summary":"深交所将对公司股票实施其他风险警示。公司股票将自2026年1月5日开市起停牌1天，自1月6日开市起复牌并被实施其他风险警示，股票简称变更为“ST得润”，股票交易日涨跌幅限制为5%。得润电子2025年累计跌幅为6.39%，最新市值40.74亿元。百利天恒解禁市值963.19亿元，居首。国联民生解禁市值为180.08亿元，解禁数量为17.71亿股，涉及43名股东，锁定期均为12个月。建设工业解禁市值为168.95亿元，解禁数量为6.3亿股，占公司总股本的60.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103075616a6ecf143&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103075616a6ecf143&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1564","01456","02615","BK1147"],"gpt_icon":0},{"id":"2600036847","title":"每周股票复盘：百利天恒（688506）拟回购股份金额不低于1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600036847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600036847?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:36","pubTimestamp":1767292571,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，百利天恒报收于338.55元，较上周的354.62元下跌4.53%。本周，百利天恒12月22日盘中最高价报355.48元。本周关注点公司公告汇总：百利天恒拟以集中竞价方式回购股份，金额不低于1亿元且不超过2亿元。公司公告汇总：公司拟申请注册发行债务融资工具，规模不超过人民币100亿元。本次发行需经公司股东会审议及中国银行间市场交易商协会注册批准，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","02615","91194"],"gpt_icon":0},{"id":"2595374220","title":"专访百利天恒创始人朱义：原始创新打造超级爆品，执掌全球话语权","url":"https://stock-news.laohu8.com/highlight/detail?id=2595374220","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595374220?lang=zh_cn&edition=full","pubTime":"2025-12-31 07:00","pubTimestamp":1767135600,"startTime":"0","endTime":"0","summary":"行业热度攀升，百利天恒创始人朱义向21世纪经济报道记者分析，“对于本土Biotech而言，关键机会在于聚焦从0到1的原始创新，在未被满足的临床需求领域建立核心技术壁垒，实现从跟跑到领跑的跨越。”朱义表示，这背后是百利天恒针对iza-bren在国内开展的临床研究，始终严格遵循国际标准推进的扎实积累。朱义透露，后续将在合适时机重启港股IPO上市，计划通过全球资本平台支撑企业长期全球化发展战略。其二，全球临床开发能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025123107024897a0dfc5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025123107024897a0dfc5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02615","91194"],"gpt_icon":0},{"id":"2595799938","title":"百利天恒：拟1亿元~2亿元回购股份 回购价格不超过546元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595799938","media":"每日经济新闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595799938?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:50","pubTimestamp":1767091842,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月30日，百利天恒(688506.SH)公告称，公司拟以集中竞价交易方式回购公司股份，回购金额不低于1亿元且不超过2亿元，回购价格不超过546元/股。回购的股份将在未来适宜时机全部用于实施员工持股计划或股权激励。若公司未能在股份回购实施结果暨股份变动公告日后3年内使用完毕已回购股份，尚未使用的已回购股份将予以注销。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512303605828117.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605828117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","688506","02615","BK0239"],"gpt_icon":0},{"id":"2595780546","title":"赴港未果后拟发债集资百亿，百利天恒意欲何为？","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780546","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595780546?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:20","pubTimestamp":1766996400,"startTime":"0","endTime":"0","summary":"计划发债集资百亿元12月28日，百利天恒发布公告称，公司拟在中国银行间市场申请注册发行不超过100亿元债务融资工具，品种包括但不限于中期票据、短期融资券等，期限最长不超过10年。赴港未果，仍需补充资金百利天恒之所以计划发债集资也和公司的基本面情况息息相关。在港股上市未果之下，百利天恒这才迅速转向了债务融资，其核心目的仍是筹集资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650512198&idx=2&sn=0b72c98e88ee94f3d340c7b65fc2f9d8&chksm=f260ee29c517673f770624625979bee57cdf604e8c999a72697592cd0329e4b11faddb869d95#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["91194","02615"],"gpt_icon":0},{"id":"2594221865","title":"百利天恒最新公告：拟申请注册发行不超过100亿元债务融资工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2594221865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594221865?lang=zh_cn&edition=full","pubTime":"2025-12-28 15:50","pubTimestamp":1766908207,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司拟在中国银行间交易市场申请注册发行债务融资工具，发行规模不超过100亿元，品种包括中期票据、短期融资券等。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800002883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","688506","BK0239","02615"],"gpt_icon":0},{"id":"2594077241","title":"每周股票复盘：百利天恒（688506）控股股东限售股将解禁并承诺不减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2594077241","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594077241?lang=zh_cn&edition=full","pubTime":"2025-12-28 02:17","pubTimestamp":1766859432,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，百利天恒报收于338.55元，较上周的354.62元下跌4.53%。本周，百利天恒12月22日盘中最高价报355.48元。公司公告汇总：控股股东朱义自愿承诺限售期满后12个月内不以任何方式减持公司股份。公司公告汇总四川百利天恒药业股份有限公司首次公开发行部分限售股将于2026年1月6日上市流通，本次解除限售股份数量为298,108,880股，占公司当前总股本的72.2034%，限售期为36个月。保荐人中信证券对本次限售股上市流通事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","02615","91194"],"gpt_icon":0},{"id":"2594378092","title":"百利天恒（688506）披露首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告，12月25日股价下跌3.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594378092","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594378092?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:07","pubTimestamp":1766671628,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，百利天恒报收于331.0元，较前一交易日下跌3.22%，最新总市值为1366.61亿元。近日，四川百利天恒药业股份有限公司发布关于首次公开发行部分限售股上市流通暨控股股东、实际控制人自愿承诺不减持的公告。公告显示，公司首次公开发行部分限售股将于2026年1月6日上市流通，本次解除限售股份数量为298,108,880股，占公司当前总股本的72.2034%，限售期为36个月。本次解除限售股东为公司控股股东、实际控制人朱义先生。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500035809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","BK0239","91194"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baili-pharm.com","compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0336},{"period":"3month","weight":0.0362},{"period":"6month","weight":0.0959},{"period":"1year","weight":0.4225},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"公司是一家聚焦于全球生物医药前沿领域，立足于解决临床未被满足的需求，具备包括小分子化学药、大分子生物药及ADC药物的全系列药品研究开发能力，并拥有从中间体、原料药到制剂一体化优势的、覆盖“研发—生产—营销”完整全生命周期商业化运营能力的生物医药企业。公司拥有两大业务板块,分别为创新生物药业务和化药制剂、中成药制剂业务板块。公司主要产品:丙泊酚乳状注射液、丙泊酚中/长链脂肪乳注射液、吸入用七氟烷、结构脂肪乳注射液(C6~24)、黄芪颗粒、盐酸胍法辛缓释片、葡萄糖电解质泡腾片。","exchange":"SEHK","name":"百利天恒","nameEN":"BIOKIN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,02615,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(02615)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(02615)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}